Quest Diagnostics (DGX)

242.56
-0.39 (-0.16%)
NYSE · Last Trade: Oct 27th, 9:54 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close242.95
Open241.96
Bid207.14
Ask247.93
Day's Range239.59 - 243.27
52 Week Range171.18 - 248.84
Volume919,018
Market Cap29.64B
PE Ratio (TTM)27.72
EPS (TTM)8.8
Dividend & Yield3.440 (1.42%)
1 Month Average Volume1,081,259

Chart

About Quest Diagnostics (DGX)

Quest Diagnostics is a leading global provider of diagnostic information services, specializing in laboratory testing and related services. The company offers a comprehensive range of medical testing, including routine blood work, genetic testing, and specialized diagnostic imaging, aimed at helping healthcare providers make informed decisions about patient care. With a vast network of laboratories and patient service centers, Quest Diagnostics plays a critical role in the healthcare ecosystem by delivering accurate and timely results, contributing to enhanced patient outcomes and supporting public health initiatives. Through their innovative technologies and dedication to quality, the company strives to advance the practice of medicine and improve overall health management. Read More

News & Press Releases

Quest Diagnostics: 3 Key Takeaways for Long-Term Investorsfool.com
Automation and direct-to-consumer expansion are offsetting wage inflation and Medicare reimbursement pressure, the dual challenge facing diagnostics providers.
Via The Motley Fool · October 22, 2026
What Quest Diagnostics (DGX) Said on Its Q3 Earnings Callmarketbeat.com
Quest Diagnostics (NYSE:DGX) reported third-quarter 2026 revenue growth of 10% and adjusted earnings-per-share growth of more than 15%, citing demand across its physician, hospital and consumer channels as well as productivity gains from automation and artificial intelligence. The company raised and
Via MarketBeat · October 22, 2026
Quest Diagnostics (DGX) Q3 2026 Earnings Call Transcriptfool.com
Revenue grew 10% as automation and AI boosted margins amid regulatory headwinds.
Via The Motley Fool · October 22, 2026
S&P 500 After-Hours Losers on Oct. 19: DGX, COP, STLD, WRBchartmill.com
Via Chartmill · October 19, 2026
Quest Diagnostics (NYSE:DGX): A Dividend Quality Pick for Income Investorschartmill.com
Via Chartmill · October 9, 2026
Quest Diagnostics (NYSE:DGX) Breakout Setup Backed by Technical Rating 7 and Setup Rating 8chartmill.com
Via Chartmill · October 2, 2026
S&P 500 Premarket Movers on Oct. 22: Allegion and Lockheed Martin Gain, Snap-on and Lam Research Fallchartmill.com
Via Chartmill · October 22, 2026
Quest’s (NYSE:DGX) Q3 2026: beats on revenue
Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 10% year on year t...
Via StockStory · October 22, 2026
Tuesday's session: gap up and gap down stock in the S&P500 indexchartmill.com
Via Chartmill · October 6, 2026
These S&P500 stocks have an unusual volume in today's sessionchartmill.com
Via Chartmill · September 22, 2026
Why Quest Diagnostics Holdings Stock Dropped Todayfool.com
The government thinks it's been overpaying Quest Diagnostics. They plan to stop doing that next year.
Via The Motley Fool · September 22, 2026
Quest Diagnostics (NYSE:DGX) Shows Dividend Quality Beyond the Headline Yieldchartmill.com
Via Chartmill · August 18, 2026
These S&P500 stocks are moving in today's sessionchartmill.com
Via Chartmill · September 22, 2026
What's going on in today's session: S&P500 gap up and gap down stockschartmill.com
Via Chartmill · September 22, 2026
Discover the top S&P500 movers in Tuesday's pre-market session.chartmill.com
Via Chartmill · September 22, 2026
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surgesmarketbeat.com
Quest Diagnostics (NYSE:DGX) CEO and President Jim Davis said the diagnostic testing company is exceeding the growth framework it outlined at its prior investor day, driven largely by organic growth, consumer-health demand and partnerships rather than a heavier-than-expected pace of acquisitions. D
Via MarketBeat · September 21, 2026
Discover which S&P500 stocks are making waves on Tuesday.chartmill.com
Via Chartmill · September 15, 2026
Quest Diagnostics CEO Sells 10,000 Shares for $2.4 Millionfool.com
J. E. Davis disposed of 8% of his direct equity stake under a pre-planned Rule 10b5-1 trading arrangement, retaining $28.9 million in company stock.
Via The Motley Fool · September 8, 2026
Why Quest Diagnostics Stock Climbed This Past Weekfool.com
Demand for medical testing services is rising.
Via The Motley Fool · July 26, 2026
Quest Diagnostics Q2 Earnings Call Highlightsmarketbeat.com
Quest Diagnostics (NYSE:DGX) reported double-digit revenue growth and raised its full-year 2026 outlook after what executives described as strong demand across its physician, hospital and consumer channels, as well as increased volume from major collaborations with Corewell Health and Fresenius Medi
Via MarketBeat · July 23, 2026
Americans Are Buying More Preventive Health Tests—and Quest Diagnostics Is Winningbenzinga.com
Quest Diagnostics (NYSE: DGX) stock jumps after Q2 earnings beat estimates and full-year 2026 guidance gets a boost.
Via Benzinga · July 23, 2026
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.chartmill.com
Via Chartmill · July 23, 2026
What's going on in today's session: S&P500 moverschartmill.com
Via Chartmill · July 23, 2026
Which S&P500 stocks are gapping on Thursday?chartmill.com
Via Chartmill · July 23, 2026
Transcript: Quest Diagnostics Q2 2026 Earnings Conference Callbenzinga.com
Quest Diagnostics (NYSE:DGX) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs.
Via Benzinga · July 23, 2026